Publikationen, an denen er mitarbeitet Antonio Fernández Nebro (33)

2022

  1. Complement component C4 structural variation and quantitative traits contribute to sex-biased vulnerability in systemic sclerosis

    npj Genomic Medicine, Vol. 7, Núm. 1

  2. Effectiveness and safety of tocilizumab in monotherapy in biologic-naïve and non-naïve patients with rheumatoid arthritis in a real-world setting

    Reumatologia Clinica, Vol. 18, Núm. 10, pp. 567-573

  3. Hospitalization and Mortality from COVID-19 of Patients with Rheumatic Inflammatory Diseases in Andalusia

    Reumatologia Clinica, Vol. 18, Núm. 7, pp. 422-428

2020

  1. A cross-disease meta-GWAS identifies four new susceptibility loci shared between systemic sclerosis and Crohn’s disease

    Scientific Reports, Vol. 10, Núm. 1

2019

  1. GWAS for systemic sclerosis identifies multiple risk loci and highlights fibrotic and vasculopathy pathways

    Nature Communications, Vol. 10, Núm. 1

  2. Prevalence of comorbidities in rheumatoid arthritis and evaluation of their monitoring in clinical practice: the spanish cohort of the COMORA study

    Reumatologia Clinica, Vol. 15, Núm. 2, pp. 102-108

2017

  1. An MIF promoter polymorphism is associated with susceptibility to pulmonary arterial hypertension in diffuse cutaneous systemic sclerosis

    Journal of Rheumatology, Vol. 44, Núm. 10, pp. 1453-1457

  2. Analysis of the common genetic component of large-vessel vasculitides through a meta-Immunochip strategy

    Scientific Reports, Vol. 7

2016

  1. Brief Report: IRF4 Newly Identified as a Common Susceptibility Locus for Systemic Sclerosis and Rheumatoid Arthritis in a Cross-Disease Meta-Analysis of Genome-Wide Association Studies

    Arthritis and Rheumatology, Vol. 68, Núm. 9, pp. 2338-2344

  2. LILRA3 deficiency is not involved in the giant cell arteritis and systemic sclerosis predisposition

    Clinical and Experimental Rheumatology

  3. Replication of PTPRC as genetic biomarker of response to TNF inhibitors in patients with rheumatoid arthritis

    Pharmacogenomics Journal, Vol. 16, Núm. 2, pp. 137-140

2015

  1. Actualización 2014 del Documento de Consenso de la Sociedad Española de Reumatología sobre el uso de terapias biológicas en la artritis reumatoide

    Reumatologia Clinica, Vol. 11, Núm. 5, pp. 279-294

  2. Comprehensive description of clinical characteristics of a large systemic lupus erythematosus cohort from the spanish rheumatology society lupus registry (RELESSER) with emphasis on complete versus incomplete lupus differences

    Medicine (United States), Vol. 94, Núm. 1, pp. e267

  3. Confirmation of CCR6 as a risk factor for anti-topoisomerase I antibodies in systemic sclerosis

    Clinical and Experimental Rheumatology, Vol. 33, pp. 31-35

  4. FCGR polymorphisms in the treatment of rheumatoid arthritis with Fc-containing TNF inhibitors

    Pharmacogenomics, Vol. 16, Núm. 4, pp. 333-345

  5. Rheumatoid arthritis response to treatment across IgG1 allotype - anti-TNF incompatibility: A case-only study

    Arthritis Research and Therapy, Vol. 17, Núm. 1

2014

  1. A genome-wide association study follow-up suggests a possible role for PPARG in systemic sclerosis susceptibility

    Arthritis Research and Therapy, Vol. 16, Núm. 1

  2. Association of FCGR2A with the response to infliximab treatment of patients with rheumatoid arthritis

    Pharmacogenetics and Genomics, Vol. 24, Núm. 5, pp. 238-245

  3. Efficacy and safety of rituximab in the treatment of non-renal systemic lupus erythematosus: A systematic review

    Seminars in Arthritis and Rheumatism, Vol. 44, Núm. 2, pp. 175-185

  4. Lack of validation of genetic variants associated with anti-tumor necrosis factor therapy response in rheumatoid arthritis: A genome-wide association study replication and meta-analysis

    Arthritis Research and Therapy, Vol. 16, Núm. 2